|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leow JJ, Martin-Doyle W, Rajagopal PS,
Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL,
Choueiri TK and Bellmunt J: Adjuvant chemotherapy for invasive
bladder cancer: A 2013 apdated systematic review and meta-analysis
of randomized trials. Eur Urol. 66:42–54. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Acunzo M, Romano G, Wernicke D and Croce
CM: MicroRNA and cancer-A brief overview. Adv Biol Regul. 57:1–9.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R,
Yang XM, Li J, Zhang YL, Wang YH, Ma MZ, et al: miR-506 acts as a
tumor suppressor by directly targeting the hedgehog pathway
transcription factor Gli3 in human cervical cancer. Oncogene.
34:717–725. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Du J, Zheng X, Cai S, Zhu Z, Tan J, Hu B,
Huang Z and Jiao H: MicroRNA506 participates in pancreatic cancer
pathogenesis by targeting PIM3. Mol Med Rep. 12:5121–5126. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang
D, Parker Kerrigan BC, Shmulevich I, Chen K, Sood AK, et al:
MiR-506 suppresses proliferation and induces senescence by directly
targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol.
233:308–318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arora H, Qureshi R and Park WY: miR-506
regulates epithelial mesenchymal transition in breast cancer cell
lines. PLoS One. 8:e642732013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yin M, Ren X, Zhang X, Luo Y, Wang G,
Huang K, Feng S, Bao X, Huang K, He X, et al: Selective killing of
lung cancer cells by miRNA-506 molecule through inhibiting NF-kB
p65 to evoke reactive oxygen species generation and p53 activation.
Oncogene. 34:691–703. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Streicher KL, Zhu W, Lehmann KP,
Georgantas RW, Morehouse CA, Brohawn P, Carrasco RA, Xiao Z, Tice
DA, Higgs BW, et al: A novel oncogenic role for the miRNA-506-514
cluster in initiating melanocyte transformation and promoting
melanoma growth. Oncogene. 31:1558–1570. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang X, Sun D, Tai J and Wang L: Ganoderic
acid A inhibits proliferation and invasion, and promotes apoptosis
in human hepatocellular carcinoma cells. Mol Med Rep. 16:3894–3900.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Winter JM, Gildea DE, Andreas JP, Gatti
DM, Williams KA, Lee M, Hu Y, Zhang S; NISC Comparative Sequencing
Program5, ; Mullikin JC, et al: Mapping complex traits in a
diversity outbred f1 mouse population identifies germline modifiers
of metastasis in human prostate cancer. Cell Syst. 4:31–45 e6.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Enokida H, Yoshino H, Matsushita R and
Nakagawa M: The role of microRNAs in bladder cancer. Investig Clin
Urol. 57 Suppl 1:S60–S76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fendler A, Stephan C, Yousef GM,
Kristiansen G and Jung K: The translational potential of microRNAs
as biofluid markers of urological tumours. Nat Rev Urol.
13:734–752. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bhardwaj A, Singh S and Singh AP:
MicroRNA-based cancer therapeutics: Big hope from small RNAs. Mol
Cell Pharmacol. 2:213–219. 2010.PubMed/NCBI
|
|
19
|
Sanli O, Dobruch J, Knowles MA, Burger M,
Alemozaffar M, Nielsen ME and Lotan Y: Bladder cancer. Nat Rev Dis
Primers. 3:170222017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Froehner M, Koch R, Heberling U, Novotny
V, Oehlschlaeger S, Hubler M, Baretton GB, Hakenberg OW and Wirth
MP: Decreased overall and bladder cancer-specific mortality with
adjuvant chemotherapy after radical cystectomy: Multivariable
competing risk analysis. Eur Urol. 69:984–987. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Scheel C and Weinberg RA: Cancer stem
cells and epithelial-mesenchymal transition: Concepts and molecular
links. Semin Cancer Biol. 22:396–403. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qian CN, Mei Y and Zhang J: Cancer
metastasis: Issues and challenges. Chin J Cancer. 36:382017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mei Y, Yang JP and Qian CN: For robust big
data analyses: A collection of 150 important pro-metastatic genes.
Chin J Cancer. 36:162017. View Article : Google Scholar : PubMed/NCBI
|
